Physician profile
Codey Pham
NPI 1841819117
$1,795.18
in general payments reported to CMS, 2019-2025
12 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $380 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,612 · Education: $183.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,612.18 |
| Education | $183.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $407.87 | 2024-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $374.01 | 2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.18 | 2024-2025 | Xifaxan |
| Abbvie INC. | $241.25 | 2025 | |
| Madrigal Pharmaceuticals | $211.20 | 2024-2025 | Rezdiffra, Resmetirom |
| Janssen Scientific Affairs, LLC | $112.49 | 2025 | Tremfya |
| Intercept Pharmaceuticals, INC. | $75.68 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.97 | 2024 | Dificid |
| Medtronic, INC. | $28.53 | 2025 | Nexpowder |
| Genzyme Corporation | $24.21 | 2024 | |
| Phathom Pharmaceuticals, INC. | $19.03 | 2024 | Voquezna |
| Ardelyx, INC. | $14.76 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Codey Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.